demonstrated that when treatment was discontinued after 10 days of continuous treatment, the regorafenib combined with anti-PD-1 treatment group still maintained tumor suppression, and the tumor volume increased only slightly until the end of the observation period (108). The gene discussed is PDCD1; the disease is neoplasm.